Handelsbanken Fonder’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-600
Closed -$330K 1625
2022
Q1
$330K Hold
600
﹤0.01% 1466
2021
Q4
$397K Buy
600
+40
+7% +$30.6K ﹤0.01% 1494
2021
Q3
$470K Hold
560
﹤0.01% 1392
2021
Q2
$711K Buy
560
+40
+8% +$45.1K ﹤0.01% 1120
2021
Q1
$570K Hold
520
﹤0.01% 1129
2020
Q4
$742K Hold
520
﹤0.01% 958
2020
Q3
$367K Buy
+520
New +$378K ﹤0.01% 1147

Other funds holding CDLX

Handelsbanken Fonder's CDLX Position: Q2 2022 in Review

Handelsbanken Fonder sold out of Cardlytics (CDLX) in Q2 2022, closing a stake of 600 shares — an estimated $330K sold.

Handelsbanken Fonder first reported a position in CDLX in Q3 2020 and held it in 7 quarters. The position peaked at $742K in Q4 2020. 138 funds tracked by Wall St. Rank hold CDLX as of Q2 2022.

  • Handelsbanken Fonder reported no remaining Cardlytics position as of Q2 2022 after selling out during the quarter.
  • Handelsbanken Fonder sold 600 Cardlytics shares in Q2 2022, an estimated $330K.
  • Handelsbanken Fonder first reported a position in Cardlytics in Q3 2020 and held it in 7 quarters.
  • Handelsbanken Fonder's Cardlytics position peaked at $742K in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Cardlytics as of Q2 2022.

Based on Handelsbanken Fonder's 13F filing for Q2 2022, filed 3 Aug 2022.